EKF Diagnostics Holdings plc (FRA:LYF)

Market Cap	121.64M +7.6%
Revenue (ttm)	59.11M +2.7%
Net Income	2.43M -66.0%
EPS	0.01 -65.8%
Shares Out	n/a
PE Ratio	50.01
Forward PE	15.29
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	0.2740
Previous Close	0.2740
Day's Range	0.2740 - 0.2740
52-Week Range	0.2520 - 0.3220
Beta	n/a
RSI	55.29
Earnings Date	Jun 16, 2026

About EKF Diagnostics Holdings

EKF Diagnostics Holdings plc engages in the design, development, manufacture, and sale of diagnostic instruments, reagents, and other ancillary products in the Americas, Europe, the Middle East, Asia, Africa, and internationally. The company offers DiaSpect Tm hand-held hemoglobin analyzer; Hemo Control, a hemoglobin and hematocrit analyzer; and HemataStat II, a microhematocrit centrifuge that provides a quantitative hematocrit reading for six blood samples. It also provides glucose and lactate analyzers, such as Biosen C-Line GP+ and C-Line Cl...

• Industry: Electromedical and Electrotherapeutic Apparatus
• Founded: 1990
• Employees: 297
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: LYF

Financial Performance

In 2025, EKF Diagnostics Holdings's revenue was 51.56 million, an increase of 2.73% compared to the previous year's 50.19 million. Earnings were 2.12 million, a decrease of -66.00%.

Financial numbers in GBP